Life Sciences AISeedWorkflowℹProxima Bio
Proxima Bio, formerly VantAI, is an AI-native platform for proximity-based drug discovery, mapping protein-protein interactions to design medicines that reshape protein networks rather than inhibit single targets.
Company snapshot
- Stage
- Seed
- Funding
- Seed · $80M · Jan 1, 2026
- Status
- published
- Updated
- Apr 24, 2026
- Views
- Category
- Life Sciences AI
- Website
- proximabio.com
What they're building
Proxima Bio, formerly VantAI, is an AI-native platform for proximity-based drug discovery, mapping protein-protein interactions to design medicines that reshape protein networks rather than inhibit single targets.
Founders
Zachary Carpenter
Co-founder & CEO
Luca Naef
Co-founder & CTO
Foundation model usage
Editorial estimates from product descriptions. Model providers and actual usage are not confirmed.
- Inferred architecture
- Agentic loops, Multimodal processing
- Estimated model demand
- High intensity
NYC footprint
- NYC presence
- NYC company or team supported by public sources. Street address has not been verified.
Funding
Latest funding: Seed · $80M · Jan 1, 2026. Total raised: $80M. Lead investor: DCVC.
AI Lab Fit
Strong fit for multimodal reasoning, biological data retrieval, molecule and protein analysis, structured extraction, and research copilots.
Sources & location evidence
Open research desk ↗Profile source review: 2026-11-04. Current AI product, canonical identity, active operations and NYC presence. Funding not rechecked unless a linked funding correction is recorded.
Notes
Proxima Bio is tagged workflow based on buyer clarity, repeat workflow activity, public activity, and fit with the AI Atlas map.
Related NYC startups
Scientific AI can become more useful by learning the mechanisms behind complex systems and using those explanations to guide new investigations.
Output Labs develops AI systems for mechanistic reasoning, aiming to model how complex systems work and apply those explanations to scientific problems.
Life Sciences AIWorkflowℹRecent Activity
Find therapeutic targets hidden in RNA splicing.
Envisagenics analyzes RNA splicing with AI to identify disease-specific drug targets, advancing therapeutic discovery for cancer and neurodegenerative conditions through its SpliceCore platform.
Life Sciences AIInfraℹRecent Activity
Drug development can advance faster when clinical assets, operational workflows, and accumulated evidence are coordinated through software rather than fragmented manual processes.
Formation Bio acquires clinical-stage medicines and develops them using an AI-native platform, combining drug selection, trial operations, and reusable data infrastructure.
Life Sciences AIWorkflowℹRecent Activity